Document is current
Any future updates will be listed below
-
Authors
Danno, Daisuke
Imai, Noboru
Kitamura, Shigekazu
Ishizaki, Kumiko
Kikui, Shoji
Takeshima, Takao
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000044096 at UMIN JapanDocuments that mention this clinical trial
Efficacy of galcanezumab in migraine central sensitization
https://doi.org/10.1038/s41598-024-72282-6
-
Funding
Funding for this research was provided by:
The Ministry of Health, Labor and Welfare, Japan (23FC1058)
- License Information
-
More Information
Article History
Received: 30 January 2024
Accepted: 5 September 2024
First Online: 18 September 2024
Competing interests
: DD serves on the advisory boards of Amgen, Daiichi Sankyo, Eli Lilly and Otsuka. DD received speaker honoraria from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka. NI received speaker honoraria from Amgen, Daiichi Sankyo, Eli Lilly and Otsuka. ShiK served on an advisory board for Eli Lilly. ShiK received speaker honoraria from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka. KI has no competing interests related to this manuscript. ShoK received speaker honoraria from Amgen, Daiichi Sankyo, Eli Lilly and Otsuka. TT is on the advisory boards of Hedgehog MedTech and Sawai. TT received speaker honoraria from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka. TT received research grants from Eisai, Eli Lilly, Shionogi, Biohaven, and Lundbeck.
: The study protocol was approved by the Ethics Committee of Tominaga Hospital (14/April/2021), and written informed consent for participation and publication was obtained from all the participants. All procedures were conducted in accordance with applicable regulations.
